FR15C0085I1 - - Google Patents

Info

Publication number
FR15C0085I1
FR15C0085I1 FR15C0085C FR15C0085I1 FR 15C0085 I1 FR15C0085 I1 FR 15C0085I1 FR 15C0085 C FR15C0085 C FR 15C0085C FR 15C0085 I1 FR15C0085 I1 FR 15C0085I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR15C0085I1 publication Critical patent/FR15C0085I1/fr
Application granted granted Critical
Publication of FR15C0085I2 publication Critical patent/FR15C0085I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR15C0085C 2004-03-24 2015-12-04 Expression optimisee de hpv 52 l1 dans une levure Active FR15C0085I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24
EP05725933A EP1730175B1 (fr) 2004-03-24 2005-03-18 Expression optimisee de hpv 52 l1 dans une levure
PCT/US2005/009199 WO2005097821A1 (fr) 2004-03-24 2005-03-18 Expression optimisee de hpv 52 l1 dans une levure

Publications (2)

Publication Number Publication Date
FR15C0085I1 true FR15C0085I1 (fr) 2016-08-01
FR15C0085I2 FR15C0085I2 (fr) 2016-11-25

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0085C Active FR15C0085I2 (fr) 2004-03-24 2015-12-04 Expression optimisee de hpv 52 l1 dans une levure

Country Status (31)

Country Link
US (2) US7700103B2 (fr)
EP (1) EP1730175B1 (fr)
JP (1) JP4833962B2 (fr)
KR (1) KR101203403B1 (fr)
CN (1) CN1934131B (fr)
AR (1) AR048191A1 (fr)
AT (1) ATE466022T1 (fr)
AU (1) AU2005230907C1 (fr)
BE (1) BE2015C066I2 (fr)
BR (1) BRPI0509079B8 (fr)
CA (1) CA2560487C (fr)
CY (2) CY1110349T1 (fr)
DE (1) DE602005020913D1 (fr)
DK (1) DK1730175T3 (fr)
ES (1) ES2343255T3 (fr)
FR (1) FR15C0085I2 (fr)
HU (1) HUS1500062I1 (fr)
IL (1) IL178140A (fr)
LT (2) LTPA2015050I1 (fr)
LU (1) LU92903I2 (fr)
MY (1) MY148656A (fr)
NL (1) NL300777I2 (fr)
NO (3) NO338055B1 (fr)
NZ (1) NZ549898A (fr)
PL (1) PL1730175T3 (fr)
PT (1) PT1730175E (fr)
RU (1) RU2373219C2 (fr)
SI (1) SI1730175T1 (fr)
TW (1) TWI349036B (fr)
WO (1) WO2005097821A1 (fr)
ZA (1) ZA200607575B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
US7709010B2 (en) 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
EP2223933B1 (fr) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Gènes codant pour la protéine majeure de capside l1 du virus du papillome humain
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
KR102222869B1 (ko) * 2010-05-14 2021-03-04 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2011149897A1 (fr) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Analyse de capture hybride à résultats rapides et sondes associées tronquées de manière stratégique
EP2589604B1 (fr) * 2010-07-02 2016-10-05 Xiamen University Protéine l1 tronquée du papillomavirus humain de type 52
US8361720B2 (en) * 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US9018451B2 (en) 2010-12-03 2015-04-28 M S Technologies, LLC Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
WO2023014853A1 (fr) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Vaccin anti-vph
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (fr) * 1988-10-26 1998-03-17 Wayne D. Lancaster Sequences d'and pour virus des papillomes humains de type 52 methode d'utilisation
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
WO1999002694A1 (fr) 1997-07-09 1999-01-21 The University Of Queensland Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible
SI1105466T1 (sl) * 1998-08-14 2006-08-31 Merck & Co Inc Postopek za ciscenje virusu podobnih delcev humanega papilomskega virusa
WO2000009157A1 (fr) 1998-08-14 2000-02-24 Merck & Co., Inc. Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
BR0112637A (pt) 2000-07-21 2003-06-10 Glaxo Group Ltd Sequências do vìrus do papiloma códon-otimizadas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
AU2004224335B2 (en) 2003-03-24 2010-01-28 Merck Sharp & Dohme Llc Optimized expression of HPV 31 L1 in yeast
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
CA2560487A1 (fr) 2005-10-20
CN1934131A (zh) 2007-03-21
CA2560487C (fr) 2013-01-29
DE602005020913D1 (de) 2010-06-10
BRPI0509079A (pt) 2007-08-21
NZ549898A (en) 2009-06-26
EP1730175A1 (fr) 2006-12-13
WO2005097821A1 (fr) 2005-10-20
NO20064815L (no) 2006-10-23
NL300777I1 (fr) 2015-12-29
CY1110349T1 (el) 2015-04-29
DK1730175T3 (da) 2010-08-23
NO2017005I1 (no) 2017-01-20
ES2343255T3 (es) 2010-07-27
CY2015052I1 (el) 2016-06-22
TW200602490A (en) 2006-01-16
US7700103B2 (en) 2010-04-20
EP1730175B1 (fr) 2010-04-28
SI1730175T1 (sl) 2010-08-31
KR101203403B1 (ko) 2012-11-21
FR15C0085I2 (fr) 2016-11-25
KR20060134120A (ko) 2006-12-27
AU2005230907C1 (en) 2016-07-28
JP4833962B2 (ja) 2011-12-07
PL1730175T3 (pl) 2010-09-30
MY148656A (en) 2013-05-15
LTPA2015050I1 (lt) 2016-01-11
TWI349036B (en) 2011-09-21
BE2015C066I2 (fr) 2024-08-08
AU2005230907A1 (en) 2005-10-20
LU92903I2 (fr) 2016-03-08
JP2007530040A (ja) 2007-11-01
US20100035818A1 (en) 2010-02-11
US20080226660A1 (en) 2008-09-18
AR048191A1 (es) 2006-04-05
NO338055B1 (no) 2016-07-25
CN1934131B (zh) 2010-12-29
RU2373219C2 (ru) 2009-11-20
HUS1500062I1 (hu) 2017-07-28
ATE466022T1 (de) 2010-05-15
CY2015052I2 (el) 2016-06-22
IL178140A (en) 2010-11-30
RU2006137363A (ru) 2008-04-27
NO2022050I1 (no) 2022-11-30
US7744892B2 (en) 2010-06-29
NL300777I2 (fr) 2015-12-29
BRPI0509079B1 (pt) 2020-05-19
LTC1730175I2 (lt) 2017-05-10
AU2005230907B2 (en) 2011-05-19
BRPI0509079B8 (pt) 2021-07-06
IL178140A0 (en) 2006-12-31
PT1730175E (pt) 2010-06-25
ZA200607575B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
BE2024C508I2 (fr)
BE2022C549I2 (fr)
BE2024C511I2 (fr)
BE2020C513I2 (fr)
BE2020C517I2 (fr)
BE2019C540I2 (fr)
BE2019C548I2 (fr)
BE2018C045I2 (fr)
BE2017C027I2 (fr)
BE2017C023I2 (fr)
BE2017C002I2 (fr)
BE2016C067I2 (fr)
BE2016C014I2 (fr)
BE2015C041I2 (fr)
BE2015C038I2 (fr)
BE2015C066I2 (fr)
BE2015C014I2 (fr)
BE2014C071I2 (fr)
BE2014C064I2 (fr)
BE2014C063I2 (fr)
BE2019C535I2 (fr)
BE2014C010I2 (fr)
BE2013C071I2 (fr)
BE2015C065I2 (fr)
BE2013C021I2 (fr)